Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
J. Acquir. Immune Defic. Syndr., Nov;58(3):261-8 (2011)
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.
J. Acquir. Immune Defic. Syndr., Dec;52(5):595-9 (2009)
Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP.
AIDS Res. Hum. Retroviruses., Dec;23(12):1499-504 (2007)
Clinical manifestations associated with HTLV type I infection: a cross-sectional study.
AIDS Res. Hum. Retroviruses., Mar;23(3):365-71 (2007)
Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
AIDS Res. Hum. Retroviruses., Mar;22(3):222-31 (2006)
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.
J. Infect. Dis., Dec;192(11):1943-9 (2005)
Coronary heart disease in HIV-infected patients.
Curr HIV/AIDS Rep., Jun;2(2):68-73 (2005)
Case-control study of diabetes mellitus in HIV-infected patients.
J. Acquir. Immune Defic. Syndr., Dec;37(4):1464-9 (2004)
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
J. Infect. Dis., Mar;191(5):686-93 (2005)
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
Clin. Pharmacol. Ther., Aug;78(2):143-53 (2005)
Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study.
J. Acquir. Immune Defic. Syndr., Dec;37(5):1604-9 (2004)
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
J. Infect. Dis., Dec;188(12):1804-14 (2003)
Bone disorders in human immunodeficiency virus infection.
Clin. Infect. Dis., 37 Suppl 2:S91-5 (2003)
Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.
J. Acquir. Immune Defic. Syndr., Aug;30(4):379-91 (2002)
Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study.
J. Infect. Dis., Aug;184(4):519-23 (2001)
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
AIDS Res. Hum. Retroviruses., Sep;21(9):757-67 (2005)
ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection.
Antivir. Ther. (Lond.)., Sep (2012)
Fractures afterantiretroviral initiation: An analysis of the ACTG longitudinal linked randomized trial (ALLRT) study.
AIDS., Aug (2012)
Oxidant stress in HIV-infected women from the Women's Interagency HIV Study.
Antivir. Ther. (Lond.)., 14(6):763-9 (2009)
Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study.
Antivir. Ther. (Lond.)., 15(4):571-7 (2010)